Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+1.38%
$383.00
100% positive prob.
5-Day Prediction
+4.67%
$395.42
100% positive prob.
20-Day Prediction
+4.62%
$395.23
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | +1.38% | +4.67% | +4.62% | 100.0% | Pending |
| Q2 2026 | BUY | +1.45% | +3.93% | +3.76% | 100.0% | Pending |
| Q2 2026 | BUY | +1.45% | +3.93% | +3.76% | 100.0% | +9.62% |
SEC 8-K filings with transcript text
Nov 5, 2026 · 100% conf.
1D
+1.38%
$383.00
Act: +5.21%
5D
+4.67%
$395.42
20D
+4.62%
$395.23
2 exhibit991-q32026earningsr.htm
Document
Exhibit 99.1
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
•Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year
•BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior year
•Diluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarter
•Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion
SAN CARLOS, Calif. – November 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026.
John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:
“Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI. We look forward to multiple catalysts in the coming months from one of the deepest pipelines in oncology, spanning hematology and solid tumors, accelerated by our differentiated capabilities in R&D, manufacturing, and commercialization.”
(Amounts in thousands of U.S. dollars and unaudited)
Three Months EndedNine Months Ended
September 30,September 30,
20262025% Change20262025% Change
Net product revenues$1,855,057 $1,395,013 33 %$5,022,180 $3,805,619 32 %
Other revenue$34,758 $17,271 101 %$86,144 $39,244 120 %
Total revenue$1,889,815 $1,412,284 34 %$5,108,324 $3,844,863 33 %
GAAP income from operations$418,675 $163,114 157 %$993,624 $262,101 279 %
Adjusted income from operations*$612,226 $341,184 79 %$1,529,649 $755,486 102 %
GAAP net income$384,706 $124,841 208 %$849,070 $220,431 285 %
Adjusted net income*$538,735 $303,663 77 %$1,358,274 $692,622 96 %
GAAP basic EPS per ADS$3.38 $1.13 199 %$7.58 $2.03 273 %
Adjusted basic EPS per ADS*$4.74 $2.76 72 %$12.12 $6.38 90 %
GAAP diluted EPS per ADS$3.28 $1.09 201 %$7.30 $1.96 272 %
Adjusted diluted EPS per ADS*$4.59 $2.65 73 %$11.68 $6.14 90 %
Free Cash Flow*$473,532 $354,469 34 %$1,069,423 $561,916 90 %
* For an explanation of our use of non-GAAP financial measures, refer to the “Note Regarding Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.
Exhibit 99.1
Third Quarter 2026 Financial Results
Product Revenue totaled $1.9 billion for the third quarter of 2026, representing growth of 33% compared to the prior-year period.
•BRUKINSA: Global sales totaled $1.4 billion for the third quarter of 2026, representing growth of 34% compared to the prior-year period; U.S. sales of BRUKINSA totaled $1.0 billion in the third quarter of 2026, representing growth of 36% compared to the prior-year period.
•TEVIMBRA (tislelizumab): Global sales totaled $243 million in the third quarter of 2026, representing growth of 28% compared to the prior-year period.
•Amgen in-licensed products: Global sales totaled $167 million in the third quarter of 2026, representing growth of 26% compared to the prior-year period.
Gross Margin as a percentage of global product sales for the third quarter of 2026 was 88%, compared to 86% in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in the Company’s portfolio. Gross margin also benefited from productivity improvements resulting in lower costs for both BRUKINSA and TEVIMBRA, which was offset by a non-cash intangible asset impairment charge of $22 million associated with our decision to discontinue promotion of POBEVCY. On an adjusted basis, which does not include depreciation and amortization, or the impairment charge, gross margin as a percentage of product sales increased to 90%, from 86% in the comparable period of the prior year.
Operating Expenses
The following table summarizes operating expenses for the third quarter of 2026:
GAAPNon-GAAP
(unaudited, in thousands, except percentages)Q3 2026Q3 2025% ChangeQ3 2026Q3 2025% Change
Research and development $660,784 $523,662 26 %$586,168 $445,904 31 %
Selling, general and administrative $593,460 $528,998 12 %$503,719 $434,484 16 %
Total operating expenses$1,254,244 $1,052,660 19 %$1,089,887 $880,388 24 %
The following table summarizes operating expenses for the year-to-date period ended September 30, 2026, and 2025:
GAAPNon-GAAP
(unaudited, in thousands, except percentages)Q3 YTD 2026Q3 YTD 2025% ChangeQ3 YTD 2026Q3 YTD 2025% Change
Aug 26, 2026 · 100% conf.
1D
+1.45%
$332.28
Act: +0.69%
5D
+3.93%
$340.39
Act: +9.62%
20D
+3.76%
$339.85
2 a20260826form8-kxexhibit991.htm
Document
Exhibit 99.1
Financial Information
On August 26, 2026, BeOne Medicines Ltd. (the “Company”) filed its 2026 Interim Report for the six months ended June 30, 2026 (the “STAR Interim Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws and regulations of the Peoples’ Republic of China (the “PRC” and the “PRC Securities Laws”). The STAR Interim Report is available to the public in Chinese language only on the website maintained by the Shanghai Stock Exchange at www.sse.com.cn.
As required by the PRC Securities Laws, the STAR Interim Report contains additional financial information regarding the Company’s research and development expenses allocated by key products and other research and development projects for the six months ended June 30, 2026 (the “Reporting Period”), prepared in accordance with the China Accounting Standards for Business Enterprises – Basic Standard (“CAS”) and other applicable PRC accounting rules, guidance and interpretations (together with CAS, “PRC GAAP”), including but not limited to the China Securities Regulatory Commission's Compilation Rule for Information Disclosure by Companies Offering Securities to the Public No. 15 – General Rules for Financial Statement (2023 revised), and Compilation Rule for Information Disclosure by Companies Offering Securities to the Public No. 24-Special Provisions on Information Disclosure in Financial Statements of Pilot Innovative Red-chip Companies on the Sci-Tech Innovation Board. The key differences between such financial information prepared in accordance with PRC GAAP and those prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for the Reporting Period, which was previously filed with the U.S. Securities and Exchange Commission, are summarized below.
Key Differences between U.S. GAAP and PRC GAAP
Share-based Compensation
Under U.S. GAAP, the Company elects to recognize share-based compensation expenses using the straight-line method for all employee equity awards granted with graded vesting based on service conditions, provided that the amount of compensation cost recognized at any date is at least equal to the portion of the grant-date value of the options that are vested as of that date.
Under PRC GAAP, the Company recognizes share-based compensation expense using the accelerated method for all employee equity awards granted with graded vesting.
Under PRC GAAP, the excess tax benefit resulting from the pre-tax deductible amount arising from U.S. employee share-based payments over the cumulative share-based payment-related expenses recognized for accounting purposes should be recorded in shareholders’ equity rather than in current income tax expenses/benefits under U.S. GAAP.
Income Taxes in the Interim Period
Under U.S. GAAP, one overall estimated annual effective tax rate should be used to determine the interim period tax expense or benefit when a company is subject to tax in one or more jurisdictions.
PRC GAAP requires that an entity determine a separate estimated average annual effective income tax rate for each taxing jurisdiction and apply it individually to the interim period pre-tax income of each jurisdiction.
Leasing
Under U.S. GAAP, as a lessee, the Company recognizes a lease liability based on the present value of the total remaining lease payments, and a corresponding right-of-use asset. The Company subsequently recognizes operating lease expenses on a straight-line basis over the lease term.
PRC GAAP requires lessees to present interest expenses on the lease liability and depreciation on the right-of-use assets separately in the statements of operations. The combination of a straight-line depreciation of the right-of-use assets and the effective interest rate method applied to the lease liability will result in a higher total charge to profit or loss in the initial years of the leases and decreasing expenses during the latter part of the lease term.
Transfer of Royalties from Collaborative Arrangement
The Company is engaged in collaborative drug development and is entitled to receive royalty revenue from drug sales during the collaboration period. In 2025, the Company transferred its royalty rights to an independent third party for a fixed upfront cash consideration.
Under U.S. GAAP, the Company records upfront payments received from the sale of future royalties as a liability. Royalty payments made to the purchaser are recorded as a reduction of the liability or accrued interest. The Company accounts for the associated interest expense under the effective interest rate method, while continuing to recognize the full amount of royalty revenue in the period in which the counterparty sells the related product and recognizes the related reven
Aug 5, 2026 · 100% conf.
1D
+1.45%
$332.28
Act: +0.69%
5D
+3.93%
$340.39
Act: +9.62%
20D
+3.76%
$339.85
2 exhibit991-q22026earningsr.htm
Document
Exhibit 99.1
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
•Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year
•BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year
•Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter
•Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion
SAN CARLOS, Calif. – August 5, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026.
John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:
“These strong second-quarter results underscore our continued growth as a global oncology leader. Our foundational hematology franchise, led by BRUKINSA, continues to gain momentum as we advance one of the industry’s deepest and most diverse pipelines. With differentiated capabilities spanning drug discovery, clinical development, manufacturing, and commercialization, we are well positioned for our next phase of global growth.”
(Amounts in thousands of U.S. dollars and unaudited)
Three Months EndedSix Months Ended
June 30,June 30,
20262025% Change20262025% Change
Net product revenues$1,679,794 $1,302,076 29 %$3,167,123 $2,410,606 31 %
Other revenue$25,277 $13,224 91 %$51,386 $21,973 134 %
Total revenue$1,705,071 $1,315,300 30 %$3,218,509 $2,432,579 32 %
GAAP income from operations$325,047 $87,885 270 %$574,949 $98,987 481 %
Adjusted income from operations*$503,029 $274,945 83 %$917,423 $414,302 121 %
GAAP net income$237,007 $94,320 151 %$464,364 $95,590 386 %
Adjusted net income*$444,497 $252,822 76 %$819,539 $388,959 111 %
GAAP basic EPS per ADS$2.12 $0.87 144 %$4.17 $0.89 369 %
Adjusted basic EPS per ADS*$3.98 $2.33 71 %$7.37 $3.61 104 %
GAAP diluted EPS per ADS$2.05 $0.84 144 %$4.01 $0.85 372 %
Adjusted diluted EPS per ADS*$3.84 $2.25 71 %$7.08 $3.48 103 %
Free Cash Flow*$435,344 $219,772 98 %$595,891 $207,447 187 %
* For an explanation of our use of non-GAAP financial measures, refer to the “Note Regarding Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.
Exhibit 99.1
Second Quarter 2026 Financial Results
Product Revenue totaled $1.7 billion for the second quarter of 2026, representing growth of 29% compared to the prior-year period.
•BRUKINSA: Global sales totaled $1.2 billion for the second quarter of 2026, representing growth of 31% compared to the prior-year period; U.S. sales of BRUKINSA totaled $893 million in the second quarter of 2026, representing growth of 31% compared to the prior-year period.
•TEVIMBRA (tislelizumab): Global sales totaled $229 million in the second quarter of 2026, representing growth of 18% compared to the prior-year period.
•Amgen in-licensed products: Global sales totaled $157 million in the second quarter of 2026, representing growth of 25% compared to the prior-year period.
Gross Margin as a percentage of global product sales for the second quarter of 2026 was 90%, compared to 87% in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in the Company’s portfolio. Gross margin also benefited from productivity improvements resulting in lower costs for both BRUKINSA and TEVIMBRA.
Operating Expenses
The following table summarizes operating expenses for the second quarter of 2026:
GAAPNon-GAAP
(unaudited, in thousands, except percentages)Q2 2026Q2 2025% ChangeQ2 2026Q2 2025% Change
Research and development $612,280 $524,896 17 %$533,950 $444,057 20 %
Selling, general and administrative $593,214 $537,913 10 %$500,674 $441,655 13 %
Total operating expenses$1,205,494 $1,062,809 13 %$1,034,624 $885,712 17 %
The following table summarizes operating expenses for the first half of 2026:
GAAPNon-GAAP
(unaudited, in thousands, except percentages)Q2 YTD 2026Q2 YTD 2025% ChangeQ2 YTD 2026Q2 YTD 2025% Change
Research and development $1,153,504 $1,006,783 15 %$999,854 $865,252 16 %
Selling, general and administrative $1,148,311 $997,201 15 %$972,667 $837,166 16 %
Total operating expenses$2,301,815 $2,003,984 15 %$1,972,521 $1,702,418 16 %
Research and Development (R&D) Expenses increased for the second quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to advancing early clinical programs into late stage and preclinical programs into the clinic. Upfront fees and milestone payments r
This page provides BeiGene Ltd. American Depositary Shares (ONC) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ONC's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.